Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience

被引:15
作者
Fattizzo, Bruno [1 ,2 ]
Levati, Giorgia Virginia [2 ]
Giannotta, Juri Alessandro [1 ]
Cassanello, Giulio [2 ]
Cro, Lilla Marcella [3 ]
Zaninoni, Anna [1 ]
Barbieri, Marzia [3 ]
Croci, Giorgio Alberto [4 ]
Revelli, Nicoletta [5 ]
Barcellini, Wilma [1 ]
机构
[1] Fdn IRCCS CaGranda Osped Maggiore Policlin, Hematol Unit, Milan, Italy
[2] Univ Milan, Dept Oncol & Hemato Oncol, Milan, Italy
[3] Fdn IRCCSCaGranda Osped Maggiore Policlin, Cytofluorimetry Serv, Cent Lab Unit, Milan, Italy
[4] Fdn IRCCS CaGranda Osped Maggiore Policlin, Pathol Unit, Milan, Italy
[5] Fdn IRCCS CaGranda Osped Maggiore Policlin, Dept Transfus Med & Hematol, Immunohematol Reference Lab, Milan, Italy
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
low-risk myelodysplastic syndromes; autoimmunity; somatic mutations; hypoplastic myelodysplastic syndromes; bone marrow microenvironment; PROGNOSTIC SCORING SYSTEM; IMMUNOLOGICAL ABNORMALITIES; MDS; MUTATIONS; CLASSIFICATION; CYCLOSPORINE; ANTIBODIES; IMMUNE; SERUM;
D O I
10.3389/fonc.2022.795955
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Low-risk myelodysplastic syndromes (LR-MDS) are a very heterogeneous disease, with extremely variable clinical features and outcome. Therapeutic strategies are still limited and mainly consist of erythropoiesis-stimulating agents (ESAs) and transfusion support. The contribution of molecular lesions and of autoimmune phenomena to pathogenesis and clinical course, including leukemic evolution, is a field of open investigation. We analyzed data from a cohort of 226 patients with LR-MDS followed at our center in the last 20 years, focusing on morphological, immunological (antiplatelets and anti-erythrocyte autoantibodies, anti-erythroblast antibodies), and molecular features. Hypoplastic bone marrow was found in 7% of the cases correlating with younger age, deeper cytopenia, lower dysplasia, and worse response to ESAs. A marker of autoimmunity was observed in 46% of the tested cases, who were younger, were less frequent dysplastic changes, and responded better to ESAs and steroids. Finally, 68% of the tested cases displayed at least one somatic mutation, most commonly SF3B1, TET2, ASXL1, and SRSF2, associated with older age, presence of neutropenia, and lower response to ESAs. Leukemic evolution (2.2%) was associated with presence of somatic mutations, and survival was favorably related to response to ESAs and transfusion independence. Overall, granular evaluation and re-evaluation are pivotal in LR-MDS patients to optimize clinical management.
引用
收藏
页数:11
相关论文
共 45 条
[11]   Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) [J].
Della Porta, M. G. ;
Tuechler, H. ;
Malcovati, L. ;
Schanz, J. ;
Sanz, G. ;
Garcia-Manero, G. ;
Sole, F. ;
Bennett, J. M. ;
Bowen, D. ;
Fenaux, P. ;
Dreyfus, F. ;
Kantarjian, H. ;
Kuendgen, A. ;
Levis, A. ;
Cermak, J. ;
Fonatsch, C. ;
Le Beau, M. M. ;
Slovak, M. L. ;
Krieger, O. ;
Luebbert, M. ;
Maciejewski, J. ;
Magalhaes, S. M. M. ;
Miyazaki, Y. ;
Pfeilstoecker, M. ;
Sekeres, M. A. ;
Sperr, W. R. ;
Stauder, R. ;
Tauro, S. ;
Valent, P. ;
Vallespi, T. ;
van de Loosdrecht, A. A. ;
Germing, U. ;
Haase, D. ;
Greenberg, P. L. ;
Cazzola, M. .
LEUKEMIA, 2015, 29 (07) :1502-1513
[12]   Cyclosporin A in myelodysplastic syndrome: a preliminary report [J].
Dixit, A ;
Chatterjee, T ;
Mishra, P ;
Choudhary, DR ;
Mahapatra, M ;
Saxena, R ;
Choudhry, VP .
ANNALS OF HEMATOLOGY, 2005, 84 (09) :565-568
[13]   Large Granular Lymphocyte Expansion in Myeloid Diseases and Bone Marrow Failure Syndromes: Whoever Seeks Finds [J].
Fattizzo, Bruno ;
Bellani, Valentina ;
Pasquale, Raffaella ;
Giannotta, Juri Alessandro ;
Barcellini, Wilma .
FRONTIERS IN ONCOLOGY, 2021, 11
[14]   Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia [J].
Fattizzo, Bruno ;
Ireland, Robin ;
Dunlop, Alan ;
Yallop, Deborah ;
Kassam, Shireen ;
Large, Joanna ;
Gandhi, Shreyans ;
Muus, Petra ;
Manogaran, Charles ;
Sanchez, Katy ;
Consonni, Dario ;
Barcellini, Wilma ;
Mufti, Ghulam J. ;
Marsh, Judith C. W. ;
Kulasekararaj, Austin G. .
LEUKEMIA, 2021, 35 (11) :3223-3231
[15]   Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome? [J].
Fattizzo, Bruno ;
Serpenti, Fabio ;
Barcellini, Wilma ;
Caprioli, Chiara .
CANCERS, 2021, 13 (01) :1-20
[16]   Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study [J].
Fattizzo, Bruno ;
Michel, Marc ;
Zaninoni, Anna ;
Giannotta, Juri A. ;
Guillet, Stephanie ;
Frederiksen, Henrik ;
Vos, Josephine M. I. ;
Mauro, Francesca R. ;
Jilma, Bernd ;
Patriarca, Andrea ;
Zaja, Francesco ;
Hill, Anita ;
Berentsen, Sigbjorn ;
Barcellini, Wilma .
HAEMATOLOGICA, 2021, 106 (02) :622-625
[17]   Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes [J].
Fenaux, Pierre ;
Platzbecker, Uwe ;
Mufti, Ghulam J. ;
Garcia-Manero, Guillermo ;
Buckstein, Rena ;
Santini, Valeria ;
Diez-Campelo, Maria ;
Finelli, Carlo ;
Cazzola, Mario ;
Ilhan, Osman ;
Sekeres, Mikkael A. ;
Falantes, Jose F. ;
Arrizabalaga, Beatriz ;
Salvi, Flavia ;
Giai, Valentina ;
Vyas, Paresh ;
Bowen, David ;
Selleslag, Dominik ;
DeZern, Amy E. ;
Jurcic, Joseph G. ;
Germing, Ulrich ;
Goetze, Katharina S. ;
Quesnel, Bruno ;
Beyne-Rauzy, Odile ;
Cluzeau, Thomas ;
Voso, Maria-Teresa ;
Mazure, Dominiek ;
Vellenga, Edo ;
Greenberg, Peter L. ;
Hellstrom-Lindberg, Eva ;
Zeidan, Amer M. ;
Ades, Lionel ;
Verma, Amit ;
Savona, Michael R. ;
Laadem, Abderrahmane ;
Benzohra, Aziz ;
Zhang, Jennie ;
Rampersad, Anita ;
Dunshee, Diana R. ;
Linde, Peter G. ;
Sherman, Matthew L. ;
Komrokji, Rami S. ;
List, Alan F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (02) :140-151
[18]   Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes [J].
Ganan-Gomez, I. ;
Wei, Y. ;
Starczynowski, D. T. ;
Colla, S. ;
Yang, H. ;
Cabrero-Calvo, M. ;
Bohannan, Z. S. ;
Verma, A. ;
Steidl, U. ;
Garcia-Manero, G. .
LEUKEMIA, 2015, 29 (07) :1458-1469
[19]   Deep sequencing and flow cytometric characterization of expanded effector memory CD8+CD57+ T cells frequently reveals T-cell receptor Vβ oligoclonality and CDR3 homology in acquired aplastic anemia [J].
Giudice, Valentina ;
Feng, Xingmin ;
Lin, Zenghua ;
Hu, Wei ;
Zhang, Fanmao ;
Qiao, Wangmin ;
Ibanez, Maria del Pilar Fernandez ;
Rios, Olga ;
Young, Neal S. .
HAEMATOLOGICA, 2018, 103 (05) :759-769
[20]   Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes [J].
Graubert, Timothy A. ;
Shen, Dong ;
Ding, Li ;
Okeyo-Owuor, Theresa ;
Lunn, Cara L. ;
Shao, Jin ;
Krysiak, Kilannin ;
Harris, Christopher C. ;
Koboldt, Daniel C. ;
Larson, David E. ;
McLellan, Michael D. ;
Dooling, David J. ;
Abbott, Rachel M. ;
Fulton, Robert S. ;
Schmidt, Heather ;
Kalicki-Veizer, Joelle ;
O'Laughlin, Michelle ;
Grillot, Marcus ;
Baty, Jack ;
Heath, Sharon ;
Frater, John L. ;
Nasim, Talat ;
Link, Daniel C. ;
Tomasson, Michael H. ;
Westervelt, Peter ;
DiPersio, John F. ;
Mardis, Elaine R. ;
Ley, Timothy J. ;
Wilson, Richard K. ;
Walter, Matthew J. .
NATURE GENETICS, 2012, 44 (01) :53-U77